N/A N=125 Microbial Basis of Systemic Malodor and "People Allergic To Me" Conditions
Nutritional and Metabolic Diseases
Primary: Gut Microbiome — 52; 64; 25; 33 Normalized OTU counts
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 Effects of Sertraline on Brain Connectivity in Adolescents With OCD
OCD
Primary: CY-BOCS Total Score at 12-weeks — 14.1; 0 units on a scale
N/A N=80 Paravertebral Block for Proximal Humeral Fracture Surgery
Proximal Humeral Fracture
Primary: Success Rate(Ability to Proceed With Surgery Without the Need for Intravenous Narcotics, General Anaesthesia, Rescue Blocks or Local Infiltration by the Surgeon) — 31…
Phase 2 N=290 Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Autism Spectrum Disorders
Primary: Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity — 8.81; 8.68; 8.97; 8.68 score on a scale — p=0.503
N/A N=30 MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer
Prostate Cancer
Primary: Feasibility of Delivering Stereotactic Body Radiotherapy(SBRT) With Simultaneous Integrated Boost(SIB). — 9; 14; 2; 5 Participants
Phase 3 N=452 A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
CMV
Primary: Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant — 155; 78 Participants
Phase 3 N=446 A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
Kidney Transplantation
Primary: Percentage of Participants Who Survive With a Functional Graft at 24 Months — 98.2; 97.3 Percentage
Phase 3 N=31 Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy
ATTR-CM · TTR-CM
Primary: Percentage of Participants With Categories of Patient Global Assessment (PGA) for Follow-up Visit: Month 12 — 0; 16.1; 9.7; 51.6 percentage of participants
Phase 2 N=25 Prevention of Skeletal Muscle Adaptations to Traumatic Knee Injury and Surgery
Anterior Cruciate Ligament Reconstruction
Primary: Cross-sectional Area of Skeletal Muscle Fibers (All Fibers) — 2827; 3318; 2206; 2376 micrometer squared — p=<0.05
Phase 2 N=9 RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
Age-related Macular Degeneration
Primary: Ocular Safety as Assessed Using Biomicroscopy to Investigate Ocular Tolerability — 0; 0; 1 Participants
Phase 2 N=3 A Long-Term Study of Rovalpituzumab Tesirine
Cancer
Primary: Number of Participants Receiving Treatment or Retreatment Who Experience a Treatment-Emergent Adverse Event (TEAE)
N/A N=20 Evaluation of the 755nm Alexandrite for Unwanted Tattoos
Unwanted, Non Cosmetic, Tattoos
Primary: Tattoo Clearance — 2.875; 4.25 score on a scale — p=.0077
Phase 3 N=562 Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity
Weight Loss
Primary: Weight Change (kg) From Baseline to Month 6, Main Effect of Time — -4.8 Kg — p=<.001
Phase 4 N=337 Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation
Acute Respiratory Failure · Intubation Complication
Primary: Number of Participants With Cardiovascular Collapse — 33; 31 Participants
Phase 2 N=183 A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
BRAF or NRAS Mutant Metastatic Melanoma
Primary: Percentage of Participants With Objective Response (OR) — 4.9; 14.5; 12.0 percentage of participants